Aethlon Medical Inc. 10-K Summary (Fiscal Year Ended March 31, 2009)
Business Context and Reporting Period
Aethlon Medical, Inc. is a development-stage medical device company focused on the Hemopurifier(R) platform, designed to selectively remove infectious viruses and toxins from human blood. The company's primary treatment focus is Hepatitis-C virus (HCV), with additional applications for bioterrorism countermeasures and cancer care. The reporting period covers the fiscal year ended March 31, 2009. The company has no revenue-generating operations and relies on financing to fund research and development.
Key Financial Metrics
- Revenue: $0 (No revenue generated for the fiscal year).
- Net Loss: $6,084,158 for the year ended March 31, 2009 (compared to $4,140,264 in 2008).
- Operating Expenses: $2,923,254.
- Cash Balance: $6,157 as of March 31, 2009.
- Working Capital: Deficit of $4,103,520.
- Accumulated Deficit: $38,311,414.
- Debt: Significant outstanding convertible notes and notes payable, many of which are past due or in default. Total convertible notes payable (net of discounts) were $2,069,720.
- Liquidity: Extremely constrained; cash on hand is insufficient to meet funding requirements for the next twelve months.
Material Changes vs. Prior Period
- Increased Net Loss: The net loss increased by approximately $1.94 million year-over-year, driven primarily by a $1.6 million non-cash loss on the extinguishment of debt and increased interest expenses due to the amortization of note discounts.
- Debt Restructuring: In December 2008, the company restructured 8% and 9% notes into 10% convertible notes, resulting in a recorded loss on extinguishment of $977,452.
- Stock-Based Compensation: Increased by $206,228 to $733,289 due to the amortization of stock options vesting during the fiscal year.
- Cash Position: Cash decreased from $254,691 in 2008 to $6,157 in 2009.
Guidance, Outlook, and Risks
- Going Concern: The independent auditors have issued an explanatory paragraph regarding the company's ability to continue as a going concern due to recurring losses, negative working capital, and the need for significant additional capital.
- Financing Needs: Management states that significant additional financing is required to sustain operations and advance product development. Without it, the company may be forced to cease operations.
- Regulatory Status: The Hemopurifier(R) is a Class III medical device requiring FDA Premarket Approval (PMA). The company has submitted an Investigational Device Exemption (IDE) but has not yet received approval for human clinical trials in the U.S.
- Capital Structure Risks: The company has a limited number of authorized shares remaining for issuance (approx. 4.7 million), which may hinder future equity financing. A large number of shares are issuable upon the exercise of options, warrants, and conversion of debt, creating significant dilution risk.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding segregation of duties in cash disbursements and a lack of sufficient accounting personnel.
Investor Verification Checklist
- Verify the company's ability to secure immediate financing given the $6,157 cash balance and $4.1 million working capital deficit.
- Confirm the status of the FDA Investigational Device Exemption (IDE) and the timeline for U.S. clinical trials.
- Assess the impact of the limited authorized share count on future capital raising capabilities.
- Review the terms of the outstanding convertible notes, particularly those in default, and the likelihood of further debt-to-equity conversions.
- Monitor the progress of remediation plans for the identified material weaknesses in internal controls.